Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (155,597)	$ (58,550)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	16,747	8,402
Amortization and impairment of internal-use software	2,078	1,106
Stock-based compensation expense	59,430	20,064
Change in fair value of warrant liabilities	0	29,294
Gain on sale of fixed assets	4	42
Gain on lease termination	0	(15)
Changes in operating assets and liabilities:
Accounts receivable (related party amounts of $(50,001) and $(25,000) for the six months ended September 30, 2022 and 2021, respectively)	(49,502)	(24,226)
Inventories	(3,017)	(11,494)
Deferred cost of revenue	914	(44)
Prepaid expenses and other current assets	4,899	(5,360)
Operating lease right-of-use assets	3,689	3,496
Other assets	(834)	(654)
Accounts payable (related party amounts of $(8,915) and $(4,422) for the six months ended September 30, 2022 and 2021, respectively)	(26,968)	(997)
Accrued and other current liabilities (related party amounts of $(3,009) and $5,545 for the six months ended September 30, 2022 and 2021, respectively)	(10,367)	(2,276)
Deferred revenue (related party amounts of $26,812 and $3,788 for the six months ended September 30, 2022 and 2021, respectively)	18,984	(3,574)
Operating lease liabilities	(4,426)	(3,696)
Other liabilities	(2,008)	45
Net cash used in operating activities	(145,974)	(107,025)
Cash flows from investing activities:
Purchases of property and equipment	(1,945)	(1,810)
Purchases of intangible assets		(5,500)
Proceeds from sale of property and equipment	2	1
Capitalized internal-use software costs	(3,008)	(1,807)
Net cash used in investing activities	(4,951)	(9,116)
Cash flows from financing activities:
Proceeds from exercise of stock options	3,944	5,624
Proceeds from issuance of common stock under employee stock purchase plan	3,238	0
Payments of deferred offering costs	0	(30,642)
Proceeds from issuance of common stock upon merger	0	309,720
Proceeds from PIPE (related party amounts of nil and $25,000 for the six months ended September 30, 2022 and 2021, respectively)	0	250,000
Net cash provided by financing activities	7,182	534,702
Effect of exchange rates on cash	1,452	0
Net increase (decrease) in cash and restricted cash	(142,291)	418,561
Cash and restricted cash—beginning of period	561,755	290,862
Cash and restricted cash—end of period	419,464	709,423
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment during the period included in accounts payable and accrued expenses	762	34
Stock-based compensation capitalized for internal-use software costs	1,320	437
Reclassification of deferred offering costs	0	3,971
Assumption of merger warrants liability	0	75,415
Conversion of redeemable convertible preferred stock to common stock	0	837,351
Cash and cash equivalents	410,891	701,050
Restricted cash, current	1,599	1,399
Restricted cash, non-current	6,974	6,974
Cash and cash equivalents	410,891
Total cash, cash equivalents and restricted cash	$ 419,464	$ 709,423